0001104659-23-103527.txt : 20230925 0001104659-23-103527.hdr.sgml : 20230925 20230925162757 ACCESSION NUMBER: 0001104659-23-103527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230921 FILED AS OF DATE: 20230925 DATE AS OF CHANGE: 20230925 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sorrento Therapeutics, Inc. CENTRAL INDEX KEY: 0000850261 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39852 FILM NUMBER: 231276120 BUSINESS ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-203-4100 MAIL ADDRESS: STREET 1: 4955 DIRECTORS PLACE CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: QUIKBYTE SOFTWARE INC DATE OF NAME CHANGE: 19920703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Scilex Holding Co CENTRAL INDEX KEY: 0001820190 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 BUSINESS PHONE: (650) 516-4310 MAIL ADDRESS: STREET 1: 960 SAN ANTONIO ROAD CITY: PALO ALTO STATE: CA ZIP: 94303 FORMER COMPANY: FORMER CONFORMED NAME: Scilex Holding Company/DE DATE OF NAME CHANGE: 20221117 FORMER COMPANY: FORMER CONFORMED NAME: Vickers Vantage Corp. I DATE OF NAME CHANGE: 20200804 4 1 tm2326753-1_4.xml FORM 4 X0508 4 2023-09-21 1 0001820190 Scilex Holding Co SCLX 0000850261 Sorrento Therapeutics, Inc. 4955 DIRECTORS PLACE SAN DIEGO CA 92121 0 0 1 0 0 Common Stock 2023-09-21 4 S 0 60068585 D 1917210 D Warrants to Purchase Common Stock 11.50 2023-09-21 4 S 0 4490617 D 2022-11-10 2027-11-10 Common Stock 4490617 0 D Pursuant to that certain Stock Purchase Agreement, dated September 21, 2023, between the Reporting Person and Scilex Holding Company ("Scilex"), Scilex purchased the following securities from the Reporting Person for an aggregate purchase price of (a) $10 million in cash; plus (b) the assumption by Scilex of $100 million of debt under the Reporting Person's non-amortizing super-priority senior secured debtor-in-possession term loan facility; plus (c) the assumption by Scilex of certain obligations of the Reporting Person for legal fees and expenses in the amount of approximately $12.25 million; plus (d) a credit bid of approximately $23 million owed to Scilex under the Reporting Person's non-amortizing super-priority junior secured term loan facility: (i) 60,068,585 shares of Common Stock of Scilex; (ii) 29,057,097 shares of Series A Preferred Stock of Scilex; and (iii) warrants exercisable for 4,490,617 shares of Common Stock of Scilex. /s/ Mohsin Y. Meghji 2023-09-25